Imatin 100 mg (Tablet)

Unit Price: ৳ 100.00 (3 x 10: ৳ 3,000.00)

Strip Price: ৳ 1,000.00

Medicine Details

Imatinib is a targeted cancer therapy and a tyrosine kinase inhibitor used for the treatment of various conditions including Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML), acute lymphoblastic leukemia (ALL), myelodysplastic/myeloproliferative diseases, systemic mastocytosis, dermatofibrosarcoma protuberans, gastrointestinal stromal tumors (GIST), etc.

Imatinib is a small molecule protein-tyrosine kinase inhibitor that potently inhibits the activity of the Bcr-Abl tyrosine kinase and several receptor tyrosine kinases, including Kit, discoidin domain receptors (DDR1 and DDR2), colony stimulating factor receptor (CSF-1R) and platelet-derived growth factor receptors alpha and beta (PDGFR-alpha and PDGFR-beta).

Concomitant administration of Imatinib and strong CYP3A4 inducers may reduce total exposure of imatinib; consider alternative agents.
Concomitant administration of Imatinib and strong CYP3A4 inhibitors may result in a significant imatinib exposure increase.
Imatinib will increase plasma concentration of CYP3A4 metabolized drugs.
Use caution when administering Imatinib with CYP2D6 substrates that have a narrow therapeutic window.

Women of childbearing potential must use effective contraception during treatment and for at least 15 days after stopping treatment with Imatinib.
Imatinib should not be used during pregnancy unless clearly necessary.
There is limited information on Imatinib distribution in human milk.
In non-clinical studies, the fertility of male and female rats was not affected, effects on human fertility not studied.

Edema and severe fluid retention have occurred.
Cytopenias, particularly anemia, neutropenia, and thrombocytopenia, have occurred.
Severe congestive heart failure and left ventricular dysfunction have been reported.
Severe hepatotoxicity, including fatalities may occur.
Grade 3/4 hemorrhage has been reported in clinical studies.
Bullous dermatologic reactions have been reported.
Hypothyroidism has been reported in patients.
Fetal harm can occur when administered to a pregnant woman.
Growth retardation occurring in children and pre-adolescents receiving Imatinib has been reported.
Tumor Lysis Syndrome needs close monitoring.
Reports of motor vehicle accidents have been received in patients receiving Imatinib.
Renal Toxicity has been reported.

Experience with doses higher than the recommended therapeutic dose is limited.
Events reported at different dose ranges include nausea, vomiting, diarrhoea, rash, pancytopenia, fatigue, muscle spasms, thrombocytopenia, increased creatine phosphokinase, increased bilirubin, gastrointestinal pain, weakness, myalgia, abdominal pain, fever, etc.